- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02159651
A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia
April 21, 2020 updated by: Astellas Pharma Inc
Specified Drug Use-results Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis
This study is to evaluate the safety and the efficacy of Prograf in patients with interstitial pneumonia associated with polymyositis / dermatomyositis in acute clinical setting.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
179
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chubu, Japan
-
Chugoku, Japan
-
Hokkaido, Japan
-
Kansai, Japan
-
Kanto, Japan
-
Kyushu, Japan
-
Shikoku, Japan
-
Tohoku, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with interstitial pneumonia associated with polymyositis/dermatomyositis who treated with Prograf
Description
Inclusion Criteria:
- Hospitalized patient
- Patient diagnosed with Interstitial pneumonia associated with polymyositis/dermatomyositis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1: Dermatomyositis group
patients with interstitial pneumonia associated with dermatomyositis
|
oral
Other Names:
|
2: Polymyositis group
patients with interstitial pneumonia associated with polymyositis
|
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: Up to three years
|
Up to three years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory function test value (%FVC, %DLco)
Time Frame: Up to three years
|
Respiratory function is evaluated by % FVC ( percent-predicted forced vital capacity) amd %DLco (diffusion capacity of CO).
|
Up to three years
|
Arterial blood gas analysis value (PaO2, AaDO2)
Time Frame: Up to three years
|
Arterial blood gas analysis by PaO2 (arterial O2 pressure) and AaDO2 (alveolar-arterial oxygen difference)
|
Up to three years
|
Chest CT findings
Time Frame: Up to three years
|
CT: computed tomography
|
Up to three years
|
Serum KL-6 value (serum SP-D value)
Time Frame: Up to three years
|
KL-6 (sialylated carbohydrate antigen KL-6) and SP-D (surfactant protein D) are used as marker of interstitial pneumonia
|
Up to three years
|
Patient disposition
Time Frame: Up to three years
|
patient disposition includes 1)number of case report forms collected, 2)number of patients analyzed for safety, 3)number of patients analysed for efficacy
|
Up to three years
|
Safety assessed by the incidence of adverse events
Time Frame: Up to three years
|
Any adverse events which include adverse events leading to death, white blood cell count, erythrocyte sedimentation rate and other abnormal findings from laboratory tests
|
Up to three years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2014
Primary Completion (Actual)
December 23, 2019
Study Completion (Actual)
December 23, 2019
Study Registration Dates
First Submitted
June 6, 2014
First Submitted That Met QC Criteria
June 6, 2014
First Posted (Estimate)
June 10, 2014
Study Record Updates
Last Update Posted (Actual)
April 22, 2020
Last Update Submitted That Met QC Criteria
April 21, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Skin Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Myositis
- Pneumonia
- Lung Diseases, Interstitial
- Dermatomyositis
- Polymyositis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Immunosuppressive Agents
- Immunologic Factors
- Calcineurin Inhibitors
- Tacrolimus
Other Study ID Numbers
- PRGI01
- 506-MA-PRGI-01 (Other Identifier: Japan Medical Affairs)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis
-
RenJi HospitalUnknownDermatomyositis | Lung; Disease, Interstitial, With FibrosisChina
-
Beijing Continent Pharmaceutical Co, Ltd.UnknownDermatomyositis Interstitial Lung Disease (Dm-ILD)China
-
Second Affiliated Hospital, School of Medicine,...RecruitingGastric Mucosal Manifestations in Patients With DermatomyositisChina
-
Jing LiangRecruitingClinically Amyopathic Dermatomyisitis(CAMD)China
-
The First Affiliated Hospital with Nanjing Medical...RecruitingInterstitial Lung Disease | Dermatomyositis, Adult TypeChina
-
Tokyo Medical and Dental UniversityAstellas Pharma Inc; Japan Medical AssociationCompletedDermatomyositis | Polymyositis | Interstitial PneumonitisJapan
-
RenJi HospitalUnknownInterstitial Lung Disease | DermatopolymyositisChina
-
Chinese PLA General HospitalRecruitingMicrobiome | Immune Function | Anti-MDA5 Antibody Positive DermatomyositisChina
-
Professor Adrian CovicFalcon Trading Iasi; Romanian Academy of Medical SciencesUnknownCOVID-19 | Pneumonia, Viral | Pneumonia, Ventilator-Associated | Flu Symptom | Flu Like Illness | Influenza With Pneumonia | Pneumonia, Interstitial | Pneumonia AtypicalItaly, Romania, United Kingdom
-
Eli Lilly and CompanyNo longer availableChronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE) | Juvenile Dermatomyositis (JDM) | Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI) | Aicardi-Goutières Syndrome (AGS)United States, United Kingdom
Clinical Trials on tacrolimus
-
Novartis PharmaceuticalsCompletedLiver Transplant RecipientBelgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
-
Novartis PharmaceuticalsCompletedLiver TransplantationUnited States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
-
Astellas Pharma IncAstellas Pharma Korea, Inc.CompletedLiver TransplantationKorea, Republic of
-
Heleen GrootjansChiesi Farmaceutici S.p.A.RecruitingLung Transplant; ComplicationsNetherlands
-
The Methodist Hospital Research InstituteVeloxis PharmaceuticalsWithdrawnAcute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
-
Taro Pharmaceuticals USACompleted
-
Peking Union Medical College HospitalUnknown
-
Technical University of MunichCompleted
-
Limerick BioPharmaCompleted
-
University of British ColumbiaPaladin Labs Inc.RecruitingLiver Transplantation | Neurotoxicity | Tremor | Tacrolimus | ImmunosuppressionCanada